N6022 is one of the most potent GSNOR inhibitors developed to date by N30 Pharma (IC50 = 20 nM) with a long duration of effect after a single dose in pre-clinical studies (24+ hours).
While initially targeted for the treatment of acute inflammatory lung conditions (asthma and COPD), it also has attractive characteristics that make it suitable for inhalational lung treatment and for the acute and chronic treatment of inflammatory bowel disease.
N6022 entered human testing in September 2010 and is currently in Phase 2 testing in inflammatory lung disease.